育龄期多囊卵巢综合征女性的骨肌减少症:一项多中心病例对照研究
这项多中心病例对照研究纳入203名18-48岁纽约州女性,比较多囊卵巢综合征(PCOS)与三种生殖表型及对照组的骨骼肌指数百分比(SMI%)和骨密度(BMD)。PCOS组SMI%、下肢SMI%及BMD均低于对照组,上肢和下肢BMD低于高雄激素血症+月经规律组。Matsuda指数在PCOS组低于对照组,且在所有组中与SMI%正相关。作者认为PCOS女性存在骨肌减少症早期征象,可能归因于胰岛素功能紊乱。
要点
- PCOS组SMI%为26.2%(95%CI 25.1-27.3),低于对照组的28.8%(95%CI 27.7-29.8)。
- PCOS组BMD为1.11 g/cm2(95%CI 1.08-1.14),低于对照组的1.17 g/cm2(95%CI 1.14-1.20)。
- Matsuda指数在PCOS组低于对照组,且在所有组中与SMI%正相关(所有P≤0.05)。
核心结论
- PCOS女性与对照组相比表现出骨肌减少症的早期征象,可能归因于胰岛素功能紊乱。
- 理解PCOS中肌肉骨骼退化的程度对于实施有针对性的干预以预防和延缓该临床人群的骨肌减少症至关重要。
研究设计与样本
- 多中心病例对照研究,纳入203名18-48岁纽约州女性。
- PCOS组定义为高雄激素血症+稀发月经;对照组为雄激素正常+月经规律;另设高雄激素血症+月经规律组和雄激素正常+稀发月经组。
主要发现
- PCOS组SMI%为26.2%(95%CI 25.1-27.3),低于对照组的28.8%(95%CI 27.7-29.8)。
- PCOS组下肢SMI%为57.6%(95%CI 56.7-60.0),低于对照组的62.5%(95%CI 60.3-64.6)。
- PCOS组BMD为1.11 g/cm2(95%CI 1.08-1.14),低于对照组的1.17 g/cm2(95%CI 1.14-1.20)。
- PCOS组上肢BMD为0.72 g/cm2(95%CI 0.70-0.74),低于高雄激素血症+月经规律组的0.77 g/cm2(95%CI 0.75-0.79);下肢BMD为1.13 g/cm2(95%CI 1.10-1.16),低于高雄激素血症+月经规律组的1.19 g/cm2(95%CI 1.16-1.22)。
- Matsuda指数在PCOS组低于对照组,且在所有组中与SMI%正相关(所有P≤0.05);仅对照组显示IGF-1与上肢BMD(r=0.84)和下肢BMD(r=0.72)相关(所有P<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Osteosarcopenia (loss of skeletal muscle and bone mass and/or function usually associated with aging) shares pathophysiological mechanisms with polycystic ovary syndrome (PCOS). However, the relationship between osteosarcopenia and PCOS remains unclear. OBJECTIVE: We evaluated skeletal muscle index% (SMI% = [appendicular muscle mass/weight (kg)] × 100) and bone mineral density (BMD) in PCOS (hyperandrogenism + oligoamenorrhea), and contrasted these musculoskeletal markers against 3 reproductive phenotypes (i): HA (hyperandrogenism + eumenorrhea) (ii); OA (normoandrogenic + oligoamenorrhea) and (iii), controls (normoandrogenic + eumenorrhea). Endocrine predictors of SMI% and BMD were evaluated across the groups. DESIGN, SETTING, AND PARTICIPANTS: Multicenter case-control study of 203 women (18-48 years old) in New York State. RESULTS: PCOS group exhibited reduced SMI% (mean [95% confidence interval (CI)]; 26.2% [25.1,27.3] vs 28.8% [27.7,29.8]), lower-extremity SMI% (57.6% [56.7,60.0] vs 62.5% [60.3,64.6]), and BMD (1.11 [1.08,1.14] vs 1.17 [1.14,1.20] g/cm2) compared to controls. PCOS group also had decreased upper (0.72 [0.70,0.74] vs 0.77 [0.75,0.79] g/cm2) and lower (1.13 [1.10,1.16] vs 1.19 [1.16,1.22] g/cm2) limb BMD compared to HA. Matsuda index was lower in PCOS vs controls and positively associated with SMI% in all groups (all Ps ≤ 0.05). Only controls showed associations between insulin-like growth factor (IGF) 1 and upper (r = 0.84) and lower (r = 0.72) limb BMD (all Ps < 0.01). Unlike in PCOS, IGF-binding protein 2 was associated with SMI% in controls (r = 0.45) and HA (r = 0.67), and with upper limb BMD (r = 0.98) in HA (all Ps < 0.05). CONCLUSIONS: Women with PCOS exhibit early signs of osteosarcopenia when compared to controls likely attributed to disrupted insulin function. Understanding the degree of musculoskeletal deterioration in PCOS is critical for implementing targeted interventions that prevent and delay osteosarcopenia in this clinical population.
引用
- Kazemi M, Jarrett BY, Parry SA, et al. Osteosarcopenia in Reproductive-Aged Women with Polycystic Ovary Syndrome: A Multicenter Case-Control Study. J Clin Endocrinol Metab. 2020. PMID: 32614948. doi:10.1210/clinem/dgaa426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。